Olema Pharmaceuticals, Inc. (OLMA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$10.36-5.73%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Olema partners with Bayer in a clinical trial collaboration. It maintains cash above $500 million. The company secured a lease for 38,176 square feet of office space. These moves support its development in women's cancer therapies.
Olema remains loss-making with EPS expected at -$2.27 in 2026 and -$2.48 in 2027. Revenue is minimal, with only $23 million estimated in 2027. Leadership changes and capital allocation issues raise risks.
The market reflects a loss-making biotech with no near-term revenue. Our view differs by emphasizing the risk from continued losses and uncertain growth from partnerships.
Breaks if: Cash position falls below $500 million
Breaks if: Lease agreement is terminated or office expansion delayed beyond FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state reflects mixed management execution and a weak recent performance, which creates uncertainty around future outcomes.
The market appears to have priced in the challenges of being a loss-making company with elevated risks. However, the recent rise in sector context suggests some optimism about potential recovery driven by sector bellwethers.
Fundamentals are likely to remain weak in the near term, given the company's loss-making status and recent earnings miss. Management's focus on advancing clinical trials may lead to increased spending, which could further impact financial performance.
The thesis hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX, as their success could provide a tailwind for OLMA. Additionally, the ongoing execution of clinical trials and management's ability to navigate risks will be critical.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss negatively impacted the outlook for OLMA. This miss adds to concerns about the company's recent financial performance, which remains weak.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Partnership dissolves or no clinical progress reported within 12 months
In the next 1-3 years, OLMA's outlook will depend heavily on sector dynamics and management execution in clinical trials. Not investment advice.